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1. Introduction  
Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (M. 
tuberculosis). When people infected with tuberculosis cough, sneeze, talk or spit, the bacilli 
are propelled into the air. Each person with active TB disease will infect on average between 
10 and 15 people every year. But people infected with TB bacilli will not necessarily become 
sick with the disease. The immune system "walls off" the TB bacilli which, protected by a 
thick waxy coat, can lie dormant for years. When the immune system is weakened, the 
chances of the infection progressing to disease are higher. 
Overall, one-third of the world's population is currently infected with the TB bacillus. 5 -
10% of people who are infected with TB bacilli (but who are not infected with HIV) become 
sick or infectious at some time during their life. People with HIV and TB infection are much 
more likely to develop TB [WHO, 2010]. 
Globally, there were an estimated 14 million prevalent cases of TB in 2009, equivalent to 200 
cases per 100 000 population. Most of the estimated number of cases in 2009 occurred in 
Asia (55%) and Africa (30%); 3 smaller proportions of cases occurred in the Eastern 
Mediterranean Region (7%), the European Region (4%) and the Region of the Americas (3%) 
[WHO, 2010]. In 2009, an estimated 1.3 million deaths (range: 1.2 – 1.5 million) occurred 
among HIV-negative cases of TB, including 0.38 million deaths (range: 0.3–0.5 million) 
among women. This is equivalent to 20 deaths per 100 000 population [WHO, 2010]. 
Until 50 years ago, there were no medicines to cure TB. Now, strains that are resistant to a 
single drug have been documented in every country surveyed and strains of TB resistant to 
all major anti-TB drugs have emerged. Drug-resistant TB is caused by inconsistent or partial 
treatment, when patients do not take all their medicines regularly for the required period 
because they start to feel better, or the doctors and health workers prescribe the wrong 
treatment regimens, or the drug supply is unreliable. A particularly dangerous form of 
drug-resistant TB is multidrug-resistant TB (MDR-TB), which is defined as the disease 
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caused by TB bacilli resistant to isoniazid and rifampicin, the two most powerful anti-TB 
drugs. Rates of MDR-TB are high in some countries, especially in the former Soviet Union, 
and threaten TB control efforts [WHO, 2010]. 
While drug-resistant TB is generally treatable, it requires extensive chemotherapy (up to two 
years of treatment) with second-line anti-TB drugs which are more costly than first-line 
drugs, and which produce adverse drug reactions that are more severe, though manageable. 
Quality assured second-line anti-TB drugs are available at reduced prices for projects 
approved by the Green Light Committee [WHO, 2010]. 
The emergence of extensively drug-resistant (XDR) TB, particularly in settings where many 
TB patients are also infected with HIV, poses a serious threat to TB control, and confirms the 
urgent need to strengthen basic TB control and to apply the new WHO guidelines for the 
programmatic management of drug-resistant TB. 
The important ramifications in the laboratory diagnosis of tuberculosis and drug resistant 
tuberculosis are: the delay in the isolation of the bacilli in culture, low sensitivity/detection 
limit of the direct smears and lack of technically trained personnel. Identification of 
tuberculosis using molecular techniques namely, polymerase chain reaction (PCR), PCR 
based restriction fragment length polymorphism (PCR-RFLP) and PCR based DNA 
sequencing are very rapid, more sensitive and reliable when compared to the conventional 
culture. There are several in house nested PCR (nPCR) standardized for the detection of M. 
tuberculosis from clinical specimens targeting MPB64 [Therese KL et al, 2005], IS6110 [Wang 
et al, 2004] and 16S rRNA [Ninet et al, 1996] genes. MPB64 is an immunogenic protein 
produced by M. tuberculosis and a few strains of M. bovis and BCG strain. IS6110 is an 
insertion element present in single or multiple copies in M. tuberculosis complex isolates. 
There are studies which reported on the lack of IS6110 insertion element in strains isolated 
from Asian population. Also there are strain variations among the M. tuberculosis isolates. 
Thus multiplex PCR or nPCR targeting more than one gene target will be a better tool for 
the detection of M. tuberculosis from direct clinical specimens.  
Drug resistance in M. tuberculosis is caused by mutations in relatively restricted regions of 
the genome. Mutations associated with drug resistance occur in rpoB for rifampicin (RIF) 
katG and the promoter region of the mabA (fabG1)-inhA operon for Isoniazid (INH), embB for 
ethambutol (EMB), pncA for pyrazinamide (PZA), rpsL and rrs for streptomycin (STR) and 
gyrA, gyrB for fluoroquinolones (FQs) such as ofloxacin (OFX) and levofloxacin (LVX) 
[Musser et al, 1995; Zhang et al, 2000].  
2. MDR-TB 
2.1 Worldwide reports on MDR-TB 
In 2008, there were an estimated 440,000 (range, 390 000-510 000) MDR-TB cases emerging 
worldwide. About 250,000 of these cases (range: 230 000–270 000) should have been reported 
to WHO, if countries had tested all the TB patients that they notified for drug resistance. 
However, only just over 30,000 MDR-TB cases (12%) were actually notified globally in 2009 
[WHO, November 2010]. 
Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India. In 2008, 
MDR-TB caused an estimated 150,000 deaths. Since 1994, 114 countries have reported 
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surveillance data on MDR-TB: 42 perform continuous surveillance of anti-TB drug resistance 
based on routine testing of all TB patients; 72 rely on periodic surveys of representative 
samples of TB patients. The Russian Federation, which was able to provide high-quality 
continuous surveillance data from 12 of its oblasts and republics, reported proportions of 
23.8–28.3% MDRTB among new TB cases in three of its oblasts in the northwest part of the 
country. Other Russian oblasts were found to have proportions of MDR-TB as low as 5.4% 
among new TB cases. Tajikistan, in its first ever survey, found proportions of 16.5% MDR-
TB among new TB cases and 61.6% MDR-TB among previously treated TB patients in 
Dushanbe city and Rudaki district, the highest proportion ever reported among previously 
treated TB patients. To date, 12 countries have reported nationwide or subnational 
proportions of MDR-TB of 6% or more among new TB cases [WHO, November 2010].  
Five of these countries also report MDR-TB proportions of 50% or more among previously 
treated cases. All of these settings are located in the eastern part of Europe or in Central 
Asia.  
2.2 Recently developed molecular techniques for the detection of drug resistance in 
tuberculosis  
2.2.1 Solid-phase Hybridization techniques 
There are currently two commercially available solid-phase hybridization techniques: the 
Line Probe Assay (INNO-LiPA Rif TB Assay; Innogenetics, Ghent, Belgium) for the 
detection of rifampicin resistance and the GenoType MTBDR assay (Hain Lifesciences, 
Nehren, Germany) for the simultaneous detection of isoniazid and rifampicin resistance. 
The LiPA assay was introduced several years ago and is based on the hybridization of 
amplified DNA from cultured strains or clinical samples to 10 probes covering the core 
region of the rpoB gene of M. tuberculosis, immobilized on a nitrocellulose strip. The 
GenoType MTBDR on the other hand, detects resistance to isoniazid and rifampicin in 
culture samples based on the detection of the most common mutations in 
the katG and rpoB genes respectively. Both assays have now been evaluated in different 
settings, giving encouraging results. In a recent study Hillemann et al evaluated the 
GenoType MTBDR assay and found that 99% of MDR strains with mutations in 
the rpoB gene and 88.4% of strains with mutations in the codon 315 of the katG gene were 
correctly identified. Correlation with DNA sequencing was 100% and compared with 
conventional tests good sensitivity and specificity were also obtained. Both solid 
hybridization methods have shown to be relatively simple to perform although basic 
expertise in molecular biology and PCR techniques is required. As with other genotypic 
methods the sensitivity of the test depends on the amount of DNA present in the sample 
and also the presence of inhibitors could cause false-negative results. 
INNOLiPA Rif. TB kit: INNOLiPA Rif. TB kit simultaneously detects the M. tuberculosis 
complex and the presence of mutations in the rpoB gene associated with resistance to 
rifampicin which is considered a marker for MDR-TB strains. The strip contains 5 probes for 
detection of sensitive genotypes (S1-S5) [Morgan et al, 2005; Makinen et al, 2006] and 4 
probes for detection of resistance genotypes (R2,R4a, R4b and R5). Rifampicin resistance is 
indicated by the absence of one or more sensitive probes, possible accompanied by the 
appearance of one or more mutant probes. 
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The GenoType MTBDR test is able to detect mutations in the rpoB gene for RIF resistance, 
and the most frequent mutation at codon 315 of the katG gene for INH resistance, either in 
isolates or clinical specimens. The specificity and sensitivity of the assay for RIF resistance 
were nearly 100%; for INH-resistance, despite a high specificity (approximately 100%), the 
sensitivity of the test ranged from 70% to 90%, depending on the prevalence of the particular 
mutation at the katG locus [Hilleman et al, 2007].  
GenoType MTBDRplus (Hain Lifescience, Germany), an advanced version of the assay, 
includes probes for the identification of other mutations in the hotspot region of the rpoB 
gene for RIF resistance, and probes to detect mutations in the promoter region of the inhA 
gene involved in INH resistance. These improvements facilitate the detection of another 10% 
to 20% of INH-resistant cases, with an enhancement in rapid MDR-TB diagnosis. 
The line probe assays are accurate and useful for rapid detection of drug resistance directly 
in clinical specimens. However, the number of genes that can be analyzed remains limited 
and the test fails to distinguish insertion mutations. Furthermore, they retain a lower 
sensitivity among acid fast bacilli-negative samples. In general, line probe assays are 
expensive and require sophisticated laboratory infrastructure. Their role and utility in low-
income, high-burden countries needs to be evaluated in field studies. 
2.2.2 Real-time Polymerase Chain Reaction techniques  
Real-time PCR techniques have also been introduced for rapid detection of drug resistance. 
Different probes have been used like the TaqMan probe, fluorescence resonance energy 
transfer (FRET) probes, molecular beacons and bioprobes. The main advantages of real-time 
PCR techniques are the speed of the test and a lower risk of contamination. The main 
disadvantages would be the requirement for expensive equipment and reagents, and the 
need for skilled technical personnel. Real-time PCR was initially applied to M. 
tuberculosis strains but more recently it has been successfully applied directly in clinical 
samples. Results could be obtained in an average of 1.5-2.0 h after DNA extraction. Real-
time PCR could eventually be implemented in reference laboratories with the required 
capacity to properly set up the technique and in settings where it can contribute to the 
management of TB patients. 
Detection of antitubercular drug resistance is vital to effective patient management. Real-
time PCR offers the potential to detect gene mutations responsible for drug resistance within 
hours from patient specimens compared with the average of 2 weeks required for traditional 
susceptibility test methods. The rpoB and katG genes are the most common M. tuberculosis 
targets utilized in real-time PCR methods and well-known mutations in these genes 
correlate with resistance to rifampin and isoniazid, respectively [Edwards et al, 2001; El-Hajj 
et al, 2001; Garcia de Viedma et al, 2002; O’Mahony et al, 2002; Piatek et al, 2002; Torres et al, 
2000; Torres et al, 2003; van Doorn et al, 2003]. The significance of other gene targets such as 
kasA, ahpC-oxyR, and inhA for the prediction of isoniazid resistance is somewhat 
controversial [Piatek et al, 2000]. Torres et al used two sets of FRET hybridization probes to 
detect rpoB mutations in 24 rifampin-resistant strains of M. tuberculosis and another set of 
FRET hybridization probes to detect katG mutations in 15 isoniazid-resistant M. tuberculosis 
strains [Torres et al, 2000]. Additionally, Garcia de Viedma et al. used two sets of rpoB 
probes and one set of katG probes to detect rpoB and katG mutations, but in a single tube, for 
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29 resistant M. tuberculosis isolates [Garcia de Viedma et al, 2002]. Since not all gene 
mutations conferring drug resistance are well characterized and are thus not amenable to 
PCR assay development, traditional culture-based susceptibility testing methods are still 
required. However, the ability to predict rifampin and isoniazid resistance up to 2 weeks 
sooner than current methods for some isolates should have significant benefit for patient 
care. 
2.2.3 Microarray  
An array is an orderly arrangement of samples where matching of known and unknown 
DNA samples is done based on base pairing rules [Heyman et al, 1999]. An array 
experiment makes use of common assay systems such as microplates or standard blotting 
membranes. The sample spot sizes are typically less than 200 microns in diameter usually 
contain thousands of spots. Thousands of spotted samples known as probes (with known 
identity) are immobilized on a solid support (a microscope glass slides or silicon chips or 
nylon membrane [Heyman et al, 1999]. The spots can be DNA, cDNA, or oligonucleotides. 
These are used to determine complementary binding of the unknown sequences thus 
allowing parallel analysis for gene expression and gene discovery. An experiment with a 
single DNA chip can provide information on thousands of genes simultaneously. An 
orderly arrangement of the probes on the support is important as the location of each spot 
on the array is used for the identification of a gene [Heyman et al, 1999]. 
Microarray technology is used in the detection of drug resistant M. tuberculosis rather than 
the detection of M. tuberculosis from clinical specimens. The TB Biochip oligonucleotide 
microarray is the most widely used Microarray for the detection of isoniazid and rifampicin 
resistance simultaneously [Garcia de Viedma D et al, 2003]. 
TB-Biochip oligonucleotide microarray for the detection of rifampicin resistant M. 
tuberculosis 
The TB-Biochip oligonucleotide microarray system is designed to detect and identify 29 
codon substitutions and 1 codon deletion distributed over 10 codon positions (507, 511, 512, 
513, 515, 516, 522, 526, 532, 533) within the rifampicin resistant determining region (RRDR). 
Each element of the microarray contains an immobilized oligonucleotide whose sequence 
matches that of either a wild-type or mutated segment of the RRDR. The use of acrylamide 
gel pads increases the robustness of the hybridization reaction. Hybridization of the 
microarray with fluorescently labeled target DNA produces a spatial pattern of fluorescence 
intensities corresponding to the efficiencies of hybridization of the labeled target DNA to the 
various oligonucleotide probes. 
In the TB-Biochip system, the fluorescence intensities are recorded using a charge-coupled 
device camera, and the relative intensities of fluorescence for the elements representing 
wildtype sequences and mutant sequences for each codon are compared using imaging 
software and automated computer-assisted interpretation of hybridization results [Garcia de 
Viedma D et al, 2003; Cavusoglu et al, 2004]. The isolate is designated RIF susceptible if the 
fluorescence of each of the wild-type elements is greater than the fluorescence of any of the 
corresponding mutant elements. The isolate is designated RIF resistant if the fluorescence of 
any one of the mutant elements is greater than the fluorescence of its corresponding wild-
type element. 
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Advantange and disadvantage of TB- biochip system 
The complete TB-Biochip system may be suitable for use in clinical laboratories with 
molecular biology expertise because it requires relatively little hands-on time for 
experimental manipulations or data analysis, tests can be run individually or in batches, and 
specialized training is not required. The observed discrepancies between the results of 
conventional DST and the TB-Biochip system (all were falsely called susceptible with the 
TB-Biochip system) likely result from the large number of mutations found in RIF-resistant 
isolates and the limited range of mutations included on the biochip. 
Although technically a solid-phase-type hybridization assay, microarrays, also known as 
biochips, have been proposed as new molecular methods for detecting drug resistance in M. 
tuberculosis. They are based on the hybridization of DNA obtained from clinical samples to 
oligonucleotides immobilized in a solid support, such as miniaturized glass slides. They 
have been mainly used to detect resistance to rifampicin. In a recent evaluation using 
oligonucleotide microarrays for analysis of drug resistance, Gryadunov et al. detected over 
95% rifampicin resistant and almost 80% isoniazid resistant M. tuberculosis isolates within 12 
h in a sample of drug-resistant isolates and clinical samples. For the time being and due to 
the high cost involved, the use of microarrays for detecting drug resistance in TB is still 
beyond the reach of most clinical mycobacteriology laboratories. 
2.3 DNA sequencing  
Sequencing DNA of PCR amplified products has been the most widely used method; it is 
accurate and reliable and it has become the gold standard for mutation detection. It has been 
performed by manual and automated procedures although the latter is now the most 
commonly used. It has been widely used for characterizing mutations in the rpoB gene in 
rifampicin-resistant strains and to detect mutations responsible for resistance to other anti-
tuberculosis drugs. It would be rather difficult, however, to implement it routinely for 
detection of drug resistance mutations for several drugs since it would involve several 
reactions for each isolate, making the cost high. 
2.3.1 DNA extraction 
DNA from clinical M. tuberculosis isolates can be extracted by using Qiagen kit (Germany) 
and also by keeping the MGIT suspension at 80˚C for 10 minutes. After 10 minutes, 
centrifuged at 3000 rpm and the supernatant can be used as template DNA for PCR. The 
procedure for extraction of DNA using Qiagen kit is mentioned below. 
Reagents and other accessories required 
a. Proteinase K 
b. Lysis buffer (AL buffer) 
c. Ethanol 
d. Washing buffer-1 (AW1 buffer) 
e. Washing buffer-2 (AW 2 Buffer) 
f. Elution buffer (AE Buffer) 
g. Minispin (eppendorff) 
h. Sterile 1.5ml vials 
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i. Micropipettes (20-200µl) 
j. Filter barriers tips (20-200µl) 
Procedure 
 Pipette 20l QIAGEN Proteinase k into the bottom of a 1.5ml microfuge tube. 
 Add 200l of the sample to the microfuge tube. Use up to 200l whole blood, plasma, 
serum, Buffy coat upto 5 X 106 lymphocytes in 200l PBS 
 Add 200l of AL buffer to the sample. Mix by pulse vortexing for 15 seconds 
 Incubate at 56° C for 10 minutes. 
 Briefly centrifuge the micro centrifuge tube to remove drops from inside of the lid. 
 Add 200l of ethanol (96-100%) to the sample, mix by pulse vortexing for 15 seconds. 
After mixing, briefly centrifuge the 1.5ml microfuge tube to remove drops from inside 
of the lid. 
 Carefully apply the mixture from step 6 to the QIAamp mini spin column (in a 2ml 
collecting tube) without wetting the rim. Close the cap, and centrifuge at 8000 rpm for 1 
min. Place the QIAamp mini spin column in a clean 2 ml collecting tube and discard the 
tube containing the filtrate. 
 Carefully open the QIAamp mini spin column and add 500l buffer AW1 without 
wetting the rim. Close the cap and centrifuge at 8000 rpm for 1min. Place the QIAamp 
mini spin column in a clean 2ml collecting tube and discard the tube containing filtrate. 
 Carefully open the QIAamp mini spin column and add 500l buffer AW2 without 
wetting the rim. Close the cap and centrifuge at 14,000 rpm for 3min, followed by an 
empty spin at 14,000 rpm for 1min. 
 Place the QIAamp mini spin column in a clean 1.5 ml microfuge tube and discard the 
tube containing filtrate. Carefully open the QIAamp mini spin column and add 200l 
AE Buffer. Incubate at room temperature for 1min, and then centrifuge at 8,000 rpm for 
1min. Discard the column and store the DNA at -20°C. 
2.3.2 PCR protocol 
Reagents and other accessories required: 
 Stock dNTPs dilution: 100 mM concentration of dNTPs- dATP, dCTP, dTTP and dGTP 
 Working standard dNTP (200µM): 2 µl of each of the stock dNTP made up to 400 µl 
using MilliQ water. 
 Forward and reverse primers 
 Taq DNA polymerase (3 units) 
 PCR Thermal cycler 
 Cyclomixer 
 Sterile 0.5 ml or 0.2 ml vials 
 Micropipettes (20-200µl, 0.5- 10µl) 
 Filter barrier tips (20-200µl) 
 Gel casting tray/trough 
 Gel combs 
 Electrophoresis tank 
 Powerpack 
 Gel documentation system 
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The PCR cocktail contained the following: 
 dNTP        8 µl 
 10X buffer (15mM Mg2+,Tris, Kcl(500 mM)-pH 8.3)    5 µl 
 Forward Primer (1 pM)       1 µl 
 Reverse Primer (1 pM)       1 µl 
 MilliQ water        30 µl 
 Taq polymerase         0.3 µl 
2.3.3 PCR protocol for amplification of embB gene using primers targeting  
640-1577 region 
PCR targeting embB gene was standardized with a specialized Taq DNA polymerase 
enzyme called “Z Taq” enzyme (Takara Bio, Ohtsu, Shiga, Japan). The Z-Taq polymerase 
offers unmatched PCR productivity, with a processing speed five times faster than those of 
other commercially available Taq polymerases. The total PCR cycle takes only 29 minutes. 
All the reagents for PCR (dNTP, 10X, Z Taq) will be provided along with the buffer. Each 50 
µl reaction contained 2.5mM dNTP, 10X, 1pM of forward and reverse primers and 2.5 Units 
of Z taq enzyme. The details of primer targeting drug resistance genes, their thermal profile 
used and the expected amplicon size are given in the Table2. 
Detection Of Amplified Products: The amplified product is subjected to electrophoresis on 
2% agarose gel incorporated with 0.5 µg/ml ethidium bromide for visualization by UV 
transilluminator (Vilber Lourmat – France). 
2.3.4 DNA sequencing of amplified products 
The term DNA sequencing refers to sequencing methods for determining the order of the 
nucleotide bases—adenine, guanine, cytosine, and thymine—in a molecule of DNA. DNA 
sequencing enables us to perform a thorough analysis of DNA because it provides us with 
the most basic information of all: the sequence of nucleotides. The classical chain-
termination method requires a single-stranded DNA template, a DNA primer, a DNA 
polymerase, radioactively or fluorescently labeled nucleotides, and modified nucleotides 
that terminate DNA strand elongation. Dye-terminator sequencing utilizes labelling of the 
chain terminator ddNTPs, which permits sequencing in a single reaction, rather than four 
reactions as in the labelled-primer method. In dye-terminator sequencing, each of the four 
dideoxynucleotide chain terminators is labelled with fluorescent dyes, each of which with 
different wavelengths of fluorescence and emission. Owing to its greater expediency and 
speed, dye-terminator sequencing is now the mainstay in automated sequencing. Its 
limitations include dye effects due to differences in the incorporation of the dye-labelled 
chain terminators into the DNA fragment, resulting in unequal peak heights and shapes in 
the electronic DNA sequence trace chromatogram after capillary electrophoresis. This 
problem has been addressed with the use of modified DNA polymerase enzyme systems 
and dyes that minimize incorporation variability, as well as methods for eliminating "dye  
www.intechopen.com
Molecular Biological Techniques for Detection of Multidrug Resistant Tuberculosis (MDR) and 
Extremely Drug Resistant Tuberculosis (XDR) in Clinical Isolates of Mycobacterium tuberculosis 
 
463 
Target genes / Primer sequence 
(5’-3’ Direction) 
Thermal 
profile 
No. of 
Cycles 
Expected 
Amplicon Size 
(bp) 
rpoB for rifampicin 
CCACCCAGGACGTGGAGGCGATCACAC 
AGTGCGACGGGTGCACGTCGCGGACCT 
 
95 ºC-5 min 
95ºC-30sec  
72ºC-1min  
72ºC -5 min 
35 286 
katG1 for isoniazid 
GCCCGAGCAACACCC 
ATGTCCCGCGTCAGG 
94˚C - 1min 
58˚C –1min 
72˚C –2 min 
35 237 
katG2 for isoniazid 
CGAGGAATTGGCCGACGAGTT 
CGGCGCCGCGGAGTTGAATGA 
94˚C - 1min 
55˚C –1min 
72˚C –2 min 
35 414 
katG3 (targeting 138 codon) for isoniazid 
CCGGCACCTACCGCATCCAC 
GCCCCAATAGACCTCATCGG 
95˚C - 1min 
60˚C –30sec 
72˚C –1 min 
30 269 
katG4 (targeting 315 codon) for isoniazid 
GAAACAGCGGCGCTGGATCGT 
GTTGTCCCATTTCGTCGGGG 
Same as above 209 
inhA for isoniazid 
CCTCGCTGCCCAGAAAGG A 
ATCCCCCGGTTTCCTCCGGT 
94˚C - 5min 
94˚C - 1min 
64˚C –1min 
72˚C –2 min 
40 248 
oxyR-ahpC for isoniazid 
GCTTGATGTCCGAGAGCAT 
GGTCGCGTAGGCAGTGCCCC 
94˚C - 2min 
94˚C - 1min 
60˚C –1min 
72˚C –2 min 
35 701 
rpsL for streptomycin 
GGCCGACAAACAGAACGT 
GTTCACCAACTGGGTGAC 
94˚C - 1min 
94˚C - 1min 
56˚C –1min 
72˚C –1 min 
72˚C – 7 min 
35 505 
rrs for streptomycin 
TTGGCCATGCTCTTGATGCCC 
TGCACACAGGCCACAAGGGA 
94˚C - 1min 
94˚C - 1min 
56˚C –1min 
72˚C –1 min 
72˚C – 7 min 
35 1140 
pncA for pyrazinamide 
GGCGTCATGGACCCTATATC 
CAACAGTTCATCCCGGTTC 
94˚C – 30 sec 
60˚C – 30 sec 
72˚C – 30 sec 
35 670 
embB for ethambutol 
CCGACCACGCTGAAACTGCTGGCGAT 
GGTGGGCAGGATGAGGTAGT 
95˚C – 5 sec 
55˚C – 10 sec 
72˚C – 10 sec 
35 937 
Table 2. Primer sets used in the study to sequence the different loci of target genes with their 
thermal profile and expected amplicon sizes[Sekiguchi et al, 2007; Siddiqi et al, 2002; 
Sreevatsan et al 1997] 
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blobs". The dye-terminator sequencing method, along with automated high-throughput 
DNA sequence analyzers, is now being used for the vast majority of sequencing projects. 
DNA sequencing involves the following steps, 
 Amplification of specific sequence from DNA 
 Electrophoresis of amplified products in 2% agarose gel 
 Elution of amplified products 
 Cycle sequencing 
 Purification of extension products 
 Sequence analysis 
Gel elution (Qiagen DNA Elution kit) 
1. The amplified product (30 l) is run on 2% agarose gel 
2. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel. 
3. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume of gel 
(100 mg is approximately 100 l). 
4. Incubate at 50ºC for 10 mins in thermal cycler (or until the gel slice has completely 
dissolved with intermittent vortexing). 
5. After the gel slice has dissolved completely, check that the color of the mixture is yellow 
(similar to buffer QG without dissolved agarose). 
6. NOTE: If the color of the mixture is orange or violet, add 10l of 3 M Sodium acetate, 
pH 5.0, and mix. The color of the mixture will turn yellow. 
7. Add one gel volume of Isopropanol to the sample and mix by repeated pipetting. 
8. Place a MinElute column in a 2ml collection tube provided in a suitable rack. 
9. Apply the sample to MinElute column, and centrifuge at 13,000 rpm for 1 minute. 
10. Discard the flow through and place the MinElute column back in the same collection 
tube. 
11. Add 500l of buffer QG to the spin column and centrifuge at 13,000 rpm for 1 minute. 
12. Discard the flow through, and place the MinElute column back in the same collection 
tube. 
13. To wash, add 750l of buffer PE to the MinElute column and centrifuge at 13,000 rpm 
for 1 minute. 
14. Discard the flow through, and place the MinElute column for an additional 1 minute at 
13,000 rpm. 
15. Place the MinElute column into a clean 1.5ml micro centrifuge tube. 
16. To elute DNA, add 10l of buffer EB (10mM Tris.Cl, pH 8.5) or water (pH 7.0-8.5) to the 
centre of the membrane, let the column stand for 1 minute, and centrifuge at 13,000 rpm 
for 1 minute. 
17. Store the eluted products at -20 ºC. 
2.3.4 Cycle sequencing 
Cycle sequencing combines amplification and enzymatic DNA sequencing using 5’ dye 
labeled terminators. 
Requirements for Cycle Sequencing 
 Forward primer or Reverse primer at the concentration of 1 picomole/μl each. 
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 Big Dye Terminator cycle sequencing Ready reaction kit (ABI prism, USA) 
Reaction Protocol 
- Ready reaction mix (2.5X RR mix)     - 2.0µl  
- 5x sequencing buffer       - 1.0µl  
- Forward/Reverse primer (1pmol/μl)     - 2.0 l 
- Milli Q water       - 2.0 µl 
- Amplified PCR product (eluted)    - 2.0 µl 
Reaction Condition for Cycle Sequencing 
 Initial Denaturation - 96˚C for 1 minute. 
 Denaturation  - 96˚C for 10 seconds. 
 Annealing   - 50˚C for 5 seconds.    25 cycles 
 Extension   - 60˚C for 4 minutes. 
 Holding Temp   - 4˚C 
Purification of Cycle Sequenced Product 
The cycle sequenced products are purified to remove the unincorporated dye terminators 
before the samples are analyzed. 
Reagents Required 
 500 mM EDTA 
 3M sodium acetate 
 Chilled ethanol 
 70% ethanol 
Procedure 
 Take 0.5ml sterile PCR vial and add 10 µl of Milli Q water. 
 Then add 2 µl of 125mM EDTA, followed by 10 µl of cycle sequenced product, 2 µl of 
3M-sodium acetate (pH 4.6) and 50 µl of chilled ethanol. Vortex well and incubate at 
room temperature (22-28ºC) for 15 minutes 
 Centrifuge at 12,000 rpm for 20 minutes. 
 Pipette out the supernatant and wash the pellet twice with 250 µl of 70% ethanol at 
12,000 rpm for 10 minutes. Care should be taken not to touch the sides of the eppendorf 
vial during pipetting. 
 The vials are then dried at 37˚C (incubator) until ethanol completely evaporates. 
Presence of ethanol will prevent complete dissolving of DNA in formamaide. 
2.3.5 Loading into DNA sequencer 
Once the ethanol is completely dried, add 10 µl of formamide. This is denatured at 95˚C 
(Thermal cycler) for 3 minutes and immediately snap cooled in ice. The sequence of the PCR 
amplified DNA is deduced with the help of the ABI Prism 3100 AVANT (Applied 
Biosystems, USA) genetic analyzer that works based on the principle of Sanger dideoxy 
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sequencing. The amplified products with the dye at the terminated 3’end is subjected to 
capillary electrophoresis by an automated sample injection. The emitted flurorescence from 
the dye labels on crossing the laser area are collected in the rate of one per second by cooled, 
charge-coupled device (CCD) camera at particular wavelength bands (virtual filters) and 
stored as digital signals on the computer for processing. 
2.3.6 Basic Local Alignment Search Tool (BLAST) analysis 
The sequences are analysed by sequence analysis softwares such as Bio Edit sequence 
alignment software or Chromas software. BLAST analysis, using pubmed, 
http://www.ncbi.nlm.nih.gov/BLAST is done to confirm the sequenced data with the 
standard strains and to determine the percentage homology.  
2.3.7 Multalin analysis 
Multalin analysis (http://multalin.toulouse.inra.fr/multalin/) to be done to identify the 
presence of polymorphism or mutation by comparing with the reference strain from 
genbank (Accession No. L27989 for rpoB, U41314 for katG, MTU16243 for inhA and oxyR-
ahpC, X70995 for rrs and rpsL, AY743320 for pncA and MTU68480 for embB). An example of 
multalin analysis targeting rpoB and katG are shown in the figure 1&2. 
 
 
Fig. 1. An example of multalin result targeting rpoB gene using forward primer showing the 
presence of most commonly reported mutation TCG→TTG (Ser531Leu). Inset enlarged view 
of the mutation.  
2.3.8 PCR based DNA sequencing for XDR-TB strains 
If an MDR-TB strain has the above-mentioned mutations, it should be screened for 
resistance to Amikacin, capreomycin, kanamycin and the fluoroquinolones by PCR based 
DNA sequencing targeting rrs, tlyA, thyA, gyrA and gyrB. The details of primer targeting 
drug resistance genes, their thermal profile used and the expected amplicon size are given in 
the Table 3. 
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Fig. 2. An example of multalin result targeting katG gene using forward primer showing the 
presence of most commonly reported mutation AGC→ACC (Ser315Thr). Inset enlarged 
view of the mutation.  
 
Target genes / Primer sequence (5’-3’ Direction) Thermal 
Profile 
No. of Cycles 
thyA (Amikacin, capreomycin, kanamycin) 
ATCGTGTGCCCCATGGTGATCT 
CTCGGTGTATTCCCGTCGACT 
95˚C – 1 min 
60˚C – 1 min 
72˚C – 1 min 
30 
tlyA(Amikacin, capreomycin, kanamycin) 
CATCGCACGTCGTCTTTC 
AATACTTTTTCTACGCGCCG 
95˚C – 1 min 
60˚C – 1 min 
72˚C – 1 min 
30 
gyrA for Moxifloxacin,Ofloxacin, Ciprofloxacin 
CAGCTACATCGACTATGCGA 
GGGCTTCGGTGTTACCTCAT 
94˚C – 1 min 
52˚C – 1 min 
72˚C – 1 min 
40 
gyrB for Moxifloxacin,Ofloxacin, Ciprofloxacin 
CCACCGACATCGGTGGATT 
CTGCCACTTGAGTTTGTACA 
94˚C – 1 min 
57˚C – 1 min 
72˚C – 1 min 
40 
Table 3. Primer sets used in the study to sequence the different loci of target genes with their 
thermal profile and expected amplicon sizes [Sekiguchi et al, 2007; Siddiqi et al, 2002; 
Sreevatsan et al 1997] 
For PCR protocol and DNA sequencing protocol, please refer to procedures 2.3.1 to 2.3.7. 
3. Conclusion  
The expectation that molecular techniques would surpass conventional methods for 
diagnosis of TB or phenotypic susceptibility testing has not yet been realized. The genetic 
basis of resistance must be understood before achieving such a goal. However, the clinician 
now has a variety of new tools to improve the diagnosis of TB and drug resistance. Most of 
them still require detailed and systematic evaluations using standard techniques as 
references before their widespread application in clinical settings. Most of these techniques 
require trained personnel and specialized equipment, hindering their application in field 
conditions, but they can be used in reference laboratories as part of the TB control programs. 
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
468 
The physician must be cautious when using results obtained by these techniques, especially 
when diagnosing drug resistance. Although it is not recommended, these molecular 
methods might be used as a complement to the standard methods in situation of difficult 
diagnosis, but never should be used solely to base such decisions. 
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